Evaluation of Skin Tests in Biotherapy Allergies | MicrobiomeTrials← Back to trialsNCT06971848
Evaluation of Skin Tests in Biotherapy Allergies
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2028-06
Enrollment target: 70 participants Locations- CHU Angers, Angers, France
Other microbiome trials you might be interested in
Advanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8Esophageal CarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaLocally Advanced Urothelial Carcinoma
Lung Non-Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Colorectal Carcinoma
Metastatic Cutaneous Melanoma
Metastatic Esophageal Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Cutaneous Melanoma
Unresectable Esophageal Squamous Cell Carcinoma
Urothelial Carcinoma
Unresectable Urothelial Carcinoma
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setti…
Jacksonville, United StatesEst. completion Dec 31, 2026
Merkel Cell CarcinomaCutaneous Squamous Cell CarcinomaBasal Cell CarcinomaTriple Negative Breast CancerNon-Small Cell Lung CancerOropharynx Squamous Cell Carcinoma
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced…
Birmingham, United StatesCompleted Oct 31, 2024